Avicanna Inc. (AVCN:CA) Q4 2025 Earnings Call Transcript

SA Transcripts159.23K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Avicanna Inc. (AVCN:CA) Q4 2025 Earnings Call April 7, 2026 8:00 AM EDT Company Participants Aras Azadian - Co-Founder, CEO & DirectorKarolina UrbanNick Hilborn - Interim Chief Financial Officer Presentation Aras AzadianCo-Founder, CEO & Director All right. We'll get started. Thank you for joining, everyone. My name is Aras Azadian, CEO, Founder of Avicanna. Some of you would know me for a long time. This is my 10th year in the role. Joined today by -- with Dr. Karolina Urban, who's our EVP of Scientific Affairs and Medical Affairs; and Nick Hilborn, who's our Interim CFO. We're going to take you over some of the corporate updates from 2025, then a little bit of an overview of where we stand as a corporation. But of course, I look forward as well into 2026. So what's coming which is very exciting. In addition to that, we're going to leave a little bit of time for Q&A at the end. So a customary disclaimer notice. But for some of you that are new to the company, I'll spend a minute or 2 and just who we are. So Avicanna is -- now we're fully vertically integrated cannabinoid-based pharma company. We have established what we believe is an industry-leading scientific platform and that his now translated into a commercial platform. This is across four different business pillars now from medical cannabis products, many there quite a brand to our medical cannabis care platform, which is my media to our pharmaceutical pipeline and, of course, our Aureus raw materials division. This is all part of an integrated commercial platform. These business units while we do operate independently, do have substantial synergistic benefits for each other business unit. This has resulted in over 50 commercial products, mainly in the Canadian market. This is part of our